Reimbursement As Important As Regulatory Risks In Investment Decisions – Venture Capitalist
This article was originally published in The Pink Sheet Daily
Executive Summary
Venture capitalists are considering whether payers will pay and what reimbursement codes are available as they assess whether to put their money in companies with new medical products, a St. Louis venture capitalist tells regulatory affairs specialists in Seattle Oct. 28.
You may also be interested in...
PDUFA V: Accelerated Approval Expansion May Outshine Rare Disease Improvements
Rare disease advocate says the focus should be on ensuring the accelerated approval expansion and surrogate endpoint guidances become FDA priorities as the rare disease drug program is set to grow under PDUFA V.
How Bad Are Biomedical Innovation Problems? Metrics Needed To Know For Sure
Panel at Brookings Institution conference says there is no comprehensive measure and the issue is more complex than just tracking R&D spending and FDA approvals.
Drug Developers Facing "Unsettled" Period Of 5 To 10 Years As CER Environment Evolves, FDA's Woodcock Says
The growing emphasis on comparative effectiveness research as well as the many unknowns on how the process is going to evolve could create a decade of unsettlement for drug development, FDA's Janet Woodcock said